Estrogen	O
modulates	O
plasminogen	O
promoter	O
activity	O
.	O


Postmenopausal	O
women	O
treated	O
with	O
estrogen	O
hormone	O
replacement	O
therapy	O
and	O
female	O
patients	O
with	O
hypoplasminogenemia	S-DISEASE
receiving	O
oral	O
contraceptives	O
show	O
increasing	O
plasminogen	O
(	O
PLG	O
)	O
concentrations	O
.	O


The	O
elevated	O
PLG	O
levels	O
are	O
in	O
contrast	O
to	O
the	O
estrogen	O
dependent	O
decline	O
of	O
lipoptrotein	O
(	O
a	O
)	O
[	O
Lp	O
(	O
a	O
)	O
]	O
,	O
whose	O
main	O
protein	O
component	O
apolipoprotein	O
(	O
a	O
)	O
[	O
APO	O
(	O
a	O
)	O
]	O
is	O
highly	O
homologous	O
to	O
PLG	O
in	O
protein	O
and	O
gene	O
structure	O
and	O
is	O
also	O
located	O
in	O
its	O
immediate	O
vicinity	O
on	O
chromosome	O
6q26	O
.	O


The	O
intergenic	O
region	O
between	O
both	O
genes	O
comprises	O
several	O
transcription	O
-	O
regulatory	O
regions	O
with	O
enhancer	O
sequences	O
that	O
increase	O
the	O
basal	O
activity	O
of	O
the	O
PLG	O
core	O
promoter	O
.	O


Using	O
luciferase	O
reporter	O
assays	O
we	O
demonstrate	O
that	O
the	O
minimal	O
PLG	O
promoter	O
is	O
insensitive	O
to	O
estrogen	O
.	O


However	O
,	O
an	O
estrogen	O
response	O
element	O
located	O
11	O
.	O
5	O
kb	O
upstream	O
of	O
the	O
PLG	O
transcription	O
start	O
site	O
is	O
able	O
to	O
convey	O
a	O
dramatic	O
estrogen	O
-	O
dependent	O
elevation	O
of	O
PLG	O
-	O
minimal	O
promoter	O
driven	O
reporter	O
gene	O
expression	O
.	O


In	O
contrast	O
,	O
the	O
activating	O
effect	O
of	O
two	O
additional	O
enhancer	O
elements	O
,	O
among	O
them	O
an	O
DNase	O
I	O
hypersensitivity	O
region	O
that	O
has	O
been	O
shown	O
to	O
regulate	O
the	O
APO	O
(	O
a	O
)	O
minimal	O
promoter	O
activity	O
,	O
is	O
abrogated	O
by	O
estrogen	O
.	O


Thus	O
,	O
the	O
identified	O
estrogen	O
-	O
responsive	O
elements	O
provide	O
a	O
gene	O
and	O
tissue	O
specific	O
framework	O
by	O
which	O
PLG	O
expression	O
is	O
regulated	O
and	O
whose	O
activity	O
is	O
orchestrated	O
by	O
yet	O
unknown	O
accessory	O
factors	O
.	O
